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The study’s aim was to image severe alcoholic hepatitis (SAH) using 111In-labelled leuco-
cytes with two objectives in mind: firstly for non-invasive diagnosis and secondly to pro-
vide a platform for experimental therapies aiming to inhibit intrahepatic neutrophil migra-
tion. 111In-leucocyte scintigraphy was performed 30 min and 24 h post-injection in 19 pa-
tients with SAH, 14 abstinent patients with alcohol-related cirrhosis and 11 normal controls.
Eleven with SAH and seven with cirrhosis also had 99mTc-nanocolloid scintigraphy. Change
in hepatic 111In radioactivity was expressed as decay-corrected 24 h:30 min count ratio
and, in SAH, compared with histological grading of steatohepatitis and expression of gran-
ulocyte marker, CD15. Hepatic microautoradiography on biopsy specimens obtained 24 h
post-injection of 111In-leucocytes was performed in one patient. Median 24 h:30 min hep-
atic 111In activity ratio was higher in SAH (2.5 (interquartile range (IQR): 1.7–4.0) compared
with cirrhotics and normal controls (1.0 (0.8–1.1) and 0.8 (0.7–0.9) respectively, P<0.0001).
In SAH, it correlated with CD15 expression (r = 0.62, P=0.023) and was higher in marked
compared with mild/moderate steatohepatitis (4.0 (3.0–4.6) compared with 1.8 (1.5–2.6),
P=0.006). Hepatic-to-splenic 99mTc count rate ratio was reduced in SAH (0.5 (0.4–1.4))
compared with cirrhotics (2.3( 0.6–3.0)) and three historic normal controls (4.2 (3.8–5.0);
P=0.003), consistent with impaired hepatic reticuloendothelial function. Scintigraphic find-
ings in SAH included prominent lung radioactivity at 30 min, likely the result of neutrophil
primimg. Microautoradiography demonstrated cell-associated 111In in areas of parenchymal
neutrophil infiltration. In conclusion, 111In-leucocyte scintigraphy can non-invasively diag-
nose SAH and could provide a platform for evaluation of novel treatments aiming to inhibit
intrahepatic neutrophil migration.
Introduction
Alcohol-related liver disease (ARLD) is a growing clinical problem. In the U.K., rates of hospitalisa-
tion and death have risen by almost 50% over the past decade, a trend which is projected to continue
[1]. Acute alcoholic hepatitis (AH) is the most florid form of ARLD. It presents with jaundice and sys-
temic upset in heavy drinkers. Clinically mild AH may resolve with abstinence but in-hospital mortal-
ity in severe AH (SAH), defined by a discriminant function (DF) ≥32, approaches 40% [2]. Prompt
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diagnosis is key to improving survival, enabling timely supportive care, nutritional support and potentially specific
medical therapies such as corticosteroids (CS) [3]. Although histology is the gold standard for diagnosing SAH, liver
biopsy is controversial because its accuracy varies from 50 to 90% [4-6]. In most instances, coagulopathy and ascites
mandate transjugular biopsy (TJB), an invasive procedure with recognised morbidity and mortality [7]. Histologi-
cal features include a neutrophil-rich parenchymal inflammatory infiltrate surrounding ballooned hepatocytes, often
with eosinophilic Mallory–Denk inclusion bodies [8]. Biopsy may yield prognostic information; for example neu-
trophil infiltration correlates positively with CS response [9] and short-term survival [10]. Doppler ultrasonography
and scintigraphywith 99mTc-colloids [11,12]may support the diagnosis but lack specificity. There is therefore a recog-
nised need for non-invasive diagnostic tests [3].
The predominating inflammatory cell infiltrating the liver in SAH is the neutrophil [8]. Almost all inflammatory
diseases involving neutrophils have been imaged at some time with radiolabelled leucocytes, most notably inflamma-
tory bowel disease in a gastroenterological context [13]. The labelled neutrophil is the effective ingredient in labelled
leucocytes, which therefore depict not only neutrophil-predominant inflammation but also physiological neutrophil
kinetics, especially neutrophil transit through the lungs [14], pooling (i.e. slow intravascular transit) in tissues (specif-
ically, liver, spleen and bone marrow) [15], and sites of physiological neutrophil destruction (again, liver, spleen and
bone marrow) [16]. Despite their widespread use in other scenarios, labelled leucocytes have never previously been
used to diagnose hepatic inflammation, probably because the liver is a major site of physiological neutrophil pooling
and destruction, and consequently regarded as beyond such inflammation-targeted imaging.
In SAH, however, we speculated that physiological neutrophil pooling and destruction would be sufficiently im-
paired to expose pathological neutrophil migration in the liver and thereby allow imaging of inflammation with
labelled leucocytes or purified neutrophils. This would open up two potentially important applications: firstly, di-
agnosing SAH non-invasively in the appropriate clinical setting, and secondly providing a platform for testing new
anti-inflammatory therapies, analogous to the use of 111In-labelled neutrophils and eosinophils in inflammatory lung
disease [17,18]. The aim of the current study, therefore, was to investigate the potential of 111In-labelled leucocytes to
non-invasively image SAH.
Methods
This was a prospective study involving three groups of patients.
1. Subjects with SAH (n=19) who were recruited from consecutive hospital admissions. SAH was suspected on clin-
ical grounds from an admission DF≥32 in active or recently abstinent heavy alcohol consumers with jaundice for
≤3 months, and confirmed wherever possible by TJB. All patients were screened to exclude other causes of liver
disease, coexistent biliary obstruction and focal hepatic lesions. Medical therapy for SAH with CS (prednisolone
40 mg daily) and/or pentoxifylline (PTX) (1200 mg daily) was prescribed at the discretion of the managing hep-
atologist. The response to treatment was determined by a fall in bilirubin level following a week of therapy [19].
Two patients received no specific treatment for SAH and three were given blinded therapy as part of another
placebo-controlled study [20], preventing assessment of treatment response. Therapy was started after imaging
in five patients, while in the remaining nine the median duration of treatment at the time of scintigraphy was 2
(1.5–6.5) days.
2. Patients with alcohol-related cirrhosis but without SAH (n=14) who were recruited following abstinence from
alcohol for ≥6 months to ensure resolution of subclinical steatohepatitis. Cirrhosis was diagnosed from the com-
bination of cutaneous stigmata of chronic liverdisease, radiological findings (irregular livermarginwith orwithout
splenomegaly) and corroborative histology, where available.
3. Controls without liver disease (n=11) who were referred for 111In-leucocyte scintigraphy for suspected prosthetic
joint infection. They had normal liver biochemistry, no risk factors for liver disease and no evidence of inflamma-
tory pathology on 111In-leucocyte scintigraphy, so could be regarded as normal controls. Those reporting alcohol
use exceeding Royal College of Physicians guidelines on safe consumption were excluded. The study received eth-
ical approval via the NHS National Research Ethics Service (reference number 08/H1107/36).
Leucocyte labelling
Autologous leucocytes fromperipheral venous bloodwere labelled in vitro under sterile conditionswith the lipophilic
chelating agents, 111In-oxine (n=41) or 111In-tropolonate (n=3, allwith SAH) according to published guidelines [21].
Briefly, erythrocytes were allowed to sediment from 35-ml anticoagulated blood, aided by the addition of 1% methyl-
cellulose. A leucocyte-rich, platelet-depleted cell pellet was obtained by centrifugation of the supernatant. The cells
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were re-suspended in saline (111In-oxine) or plasma (111In-tropolonate) and incubatedwith∼25 MBq of 111In-chelate
for 15 min, before addition of autologous platelet-poor plasma. The labelled leucocytes were pelleted, supernatant as-
pirated, and cell-associated and unbound radioactivity measured to calculate labelling efficiency. 111In-labelled leu-
cocytes were re-suspended in a further 3 ml of platelet-poor plasma and injected intravenously. The administered
radioactivity was ∼20 MBq, giving a radiation exposure of ∼7 mSv.
111In-leucocyte imaging protocol
Static planar images of the chest and abdomen were obtained 30 min and 24 h after administration of labelled leuco-
cytes using a dual-headed γ camera (SMV DSTXL or GE Discovery NM630) with medium energy collimators and
a 10-min acquisition time. To assess labelled cell viability, the recovery of cell-bound label was determined from pe-
ripheral venous blood samples obtained 45 min post injection and expressed as a percentage of administered activity.
111In-leucocyte image analysis
Tissue-associated radioactivity (expressed as mean counts per pixel) was determined frommanually defined regions
of interest (ROI) over homogeneous areas of liver, spleen and lungs. The geometric mean of anterior and posterior
counts was corrected for physical radionuclide decay and background activity. The change in liver-associated radioac-
tivity between the two imaging times was expressed as the 24 h:30 min ratio of activities.
99mTc-nanocolloid scintigraphy
99mTc-nanocolloid scintigraphy was performed after completion of 111In-leucocyte scintigraphy in 11 patients with
SAH and 7 abstinent patients with cirrhosis. Abdominal γ camera images (SMV DSTXL) were acquired 20 min post
injection of 80 MBq 99mTc-nanocolloid (Nanocoll, GE Healthcare, Amersham, U.K.; radiation exposure ∼1 mSv)
using low-energy high-resolution collimation. Down-scatter from the 111In photopeak accounted for<15% of 99mTc
tissue activity. Geometric means of counts per pixel were calculated for liver and spleen in the same ROI as above and
expressed as liver:spleen ratio.
Liver biopsy
TJB (radiation exposure ∼10 mSv) was performed in patients with SAH within 1 week of 111In-leucocyte scintigra-
phy. Independent biopsy interpretation was undertaken by two histopathologists blinded to the other’s findings and
to scintigraphy. SAH was defined as the coexistence of steatosis, hepatocyte ballooning and lobular neutrophil infil-
tration [3]. Histological features of steatohepatitis, including hepatocyte ballooning, lobular inflammation, steatosis,
canalicular cholestasis, ductular cholestasis and cholangiolitis, were assessed according to recently described crite-
ria [4]. The severity of steatohepatitis was semiquantificatively classified as mild, moderate or marked according to
whether foci of infiltrating parenchymal neutrophils were sparse, moderate or abundant. Cells positive for granulo-
cyte marker CD15 were counted in five to ten non-consecutive high-power fields in 13 patients in whom sufficient
biopsy material was available for immunohistochemical staining, and the median count averaged between the two
histopathologists.
Microautoradiography
To determine the intrahepatic fate of 111In-leucocytes in SAH, microautoradiography was performed on biopsy spec-
imens obtained 24 h post-injection of labelled leucocytes in a single patient. Formalin-fixed liver sections (3 μm
thickness) were placed on positively charged adhesive slides, de-waxed and a radiosensitive emulsion (Ilford K2,
Harman Technology, U.K.) applied in dark room conditions. Microautoradiographs were exposed in dry, dark con-
ditions for 2 weeks, following which they were fixed, developed, dried, post stained with H&E and inspected for foci
of radioactivity.
Statistical analysis
Data are presented as mean+− S.D. or median (interquartile range). Parametric data were compared using Student’s t
test or ANOVA and non-parametric data usingMann–WhitneyU or Kruskal–Wallis tests.Correlationwas quantified
using Pearson’s correlation coefficient (r) or Spearman’s rho (ρ) for parametric and non-parametric data respectively.
Interobserver agreement of categorical histopathology data was assessed using the κ statistic (κ). Reported P-values
are two-tailed.
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Table 1 Demographics and patient characteristics at recruitment
SAH (n=19) Abstinent cirrhosis (n=14) Normal controls (n=11) P
Age (years) 50.3 +− 9.8 55.7 +− 8.9 64.0 +− 14.9* 0.009
Male gender 14 (73.7%) 11 (78.6%) 7 (63.6%) 0.702
Ascites 11 (57.9%)* 2 (14.3%) - 0.015
SIRS 4 (21.1%) - -
Child-Pugh score 10 (8–11)* 5 (5–6) - <0.0001
MELD score 23 (22–27)* 8.8 (7.4–9.3) - <0.0001
DF 52 (44–75) - - -
GAHS 9 (8–10) - - -
GAHS ≥ 9 12 (63.2%) - - -
Leucocyte count (× 109/l) 12.6 (9.3–15.9)* 6.6 (5.6–7.6) 7.0 (6.3–8.7) <0.001
Neutrophil count (× 109/l) 9.8 (7.1–13.3)* 3.9 (2.6–4.9) 4.3 (3.7–5.5) <0.001
Platelet count (× 109/l) 158 (106–264) 136 (91–194)* 239 (174–287) 0.047
INR 1.8 (1.6–2.1)* 1.1 (1.1–1.2) 1.1 (1.0–1.1) <0.0001
Bilirubin (μmol/l) 288 (202–451)* 10 (8–17) 7 (4–11) <0.0001
Albumin (g/l) 29 (27–34)* 43.5 (37–46) 43 (42–44) <0.0001
Creatinine (μmol/l) 56 (47–102) 80.5 (62–107) 78 (58–81) 0.085
ALT (U/l) 63 (49–80)* 17.5 (15–32) 20 (15–22) <0.0001
AST (U/l) 171 (117–220)* 36.5 (25–46) 18 (14–20) <0.0001
Data are presented as mean +− S.D., median (IQR) or number (%). Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase;
GAHS, Glasgow alcoholic hepatitis score; INR, international normalised ratio; IQR, interquartile range; MELD, modified end-stage liver disease score;
SIRS, more than or equal to two features of the systemic inflammatory response syndrome at recruitment.
Normal values: bilirubin 0–21 μmol/l, INR 0.8–1.2, albumin 35–52 g/l, ALT 0–41 iu/l, AST 0–40 iu/l, creatinine 62–106 μmol/l, leucocyte count 4–11 ×
109/l, neutrophil count 2–7.5 × 109/l, platelet count 150–450 109/l.
*P<0.05.
Results
Patients
Baseline characteristics and demographic data are shown in Table 1. Median alcohol consumption prior to admis-
sion was 144 g/day (80–200) for 10 years [5-15]. Four abstinent cirrhotics had histologically confirmed disease. The
diagnosis in the remaining seven rested on clinical and radiological grounds.
In patients with SAH, the median admission DF was 52 (44–75); the Glasgow Alcoholic Hepatitis Score (GAHS)
[22] was ≥9 in 12 and modified end-stage liver disease (MELD) [23] score ≥21 in 16. Four (21%) had evidence of
the systemic inflammatory response syndrome (SIRS) and two had active infection (limb cellulitis and spontaneous
bacterial peritonitis (SBP)). Peripheral blood leucocyte counts were significantly higher in SAH than in either of
the other groups (Table 1; P<0.001). Normal controls were significantly older than either cohort with liver disease
(P=0.009), consistent with the population referred for investigation of prosthetic joint pain.
111In-labelled leucocyte scintigraphy
Labelling efficiency was broadly similar among the three patient groups: 89 (85–92)%, 84 (81–85)% and 86 (81–88)%.
Labelled cell recovery, however, was significantly higher in SAH (57 (48–63)%) compared with abstinent cirrhotics
and normal controls (38 (26–46)% and 38 (34–44)%, respectively, P=0.002),
Normal 111In-leucocyte scintigraphy 30-min post injection shows prominent activity in liver and spleen, and faint
diffuse activity in the lungs. At 24 h, the diffuse lung activity disappears and bone marrow activity becomes evident
(Figure 1). Liver activity falls slightly while spleen remains largely unchanged, suggesting that leucocyte pooling is
broadly matched by neutrophil destruction [13].
The 24 h:30 min activity ratio in the liver was significantly higher in SAH (2.5 (1.7–4.0) compared with abstinent
cirrhotics (1.0 (0.8–1.1)) and controls (0.8 (0.7–0.9), P<0.0001; Figures 2 and 3). Scintigraphic appearances in SAH
were similar between 111In-oxine and 111In-tropolone radiolabelling (Figure 2). Two abstinent cirrhotics had decom-
pensated liver disease with diuretic-refractory ascites and liver synthetic impairment (both Child–Pugh class B). The
24 h:30 min ratio in these two individuals (1.08 and 1.37) was not significantly higher than in compensated cirrhosis
(median 0.96 (0.78–0.99), P=0.067) and remained substantially lower than the cohort with SAH (P=0.025).
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Figure 1. Physiological 111In-labelled leucocyte distribution
γ camera images (anterior and posterior projections) obtained 30min and 24 h post injection of autologous 111In-labelled leucocytes
in a normal control. Liver: open arrows; spleen: closed arrows. Hepatic and splenic activities reflect physiological leucocyte pooling
at 30 min and cell destruction at 24 h. Hepatic activity remains unchanged or decreases between the two time points. Lung activity
can be seen faintly at 30 min.
Prominent diffuse pulmonary activity at 30 min, which cleared by 24 h, was a frequent finding in SAH (Figure
2) and occurred to a lesser degree in abstinent cirrhotics. Median lung-associated radioactivity at 30 min (expressed
relative to splenic activity) was significantly higher in SAH (20 (15–26)%) than normal controls (14.5 (13–16)%;
P=0.02), but didnot differ significantly from abstinent cirrhotics (18 (12.5–25)%,P=0.38). By 24 h, lung radioactivity
had decreased the 24 h:30 min hepatic activity ratio in patients with SAH, abstinent cirrhotics and normal controls
(bars depict median value, whiskers show interquartile range (IQR)). Similarly in all three groups but could not be
quantified because of overlying physiological activity in chest wall bone marrow.
Abnormal gut-associated radioactivity 24 h post-injection was observed in four patients with SAH (Figure 2).
Delayed imaging at 48–72 h demonstrated distal transit of 111In within bowel, in keeping with access of labelled
leucocytes into bowel.
Liver histology in SAH
Clinical deterioration after 111In-leucocyte scintigraphy precluded TJB in two patients with SAH, leaving 17 with his-
tology. Themajority had underlying advanced hepatic fibrosis or cirrhosis and all exhibited some degree of steatohep-
atitis, judged to bemarked in seven (Table 2). Interobserver agreement of fibrosis stage, steatosis grade, steatohepatitis
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 2. Examples of 111In-leucocyte scintigraphy appearances in SAH compared with normal and cirrhotic controls
Example anterior γ camera images following 111In-leucocyte administration with corresponding 24 h:30 min hepatic activity ratios in
normal control (A), abstinent control with compensated alcohol-related cirrhosis (B), patients with SAH studied using 111In-oxine la-
belling (C) and 111In-tropolonate labelling (D). Extrahepatic findings in SAH included prominent lung activity at 30 min post-injection
(arrows) and gut activity at 24 h (circled) (E).
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Figure 3. 24 hour : 30 minute liver activity ratios at 111In-leucocyte scintigraphy in SAH, compensated cirrhosis and normal
controls
The 24 h:30 min ratios were significantly higher in severe AH than controls with inactive cirrhosis and normal controls. Bars depict
median value, whiskers IQR (interquartile range).
severity and presence of Mallory’s hyaline was high (κ ≥ 0.5), but there was substantial variability in assessment of
ballooning grade, degree of canalicular cholestasis and the presence of cholangiolitis and Councilman bodies (κ ≤
0.2 in all).
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Table 2 Summary of dual histopathologist liver biopsy interpretation in SAH (n=17)
Histological parameter Pathologist #1 n (%) Pathologist #2 n (%) Agreement κ (P)
Ishak fibrosis stage
Cirrhosis 9 (52.9%) 10 (58.8%) 0.538
Stage 5 7 (41.2%) 2 (11.8%) (P<0.0001)
Stage 4 - 1 (5.9%)
Stage 3 - 3 (17.6%)
Stage 2 1 (5.9%) 1 (5.9%)
Steatosis (parenchymal involvement)
<5% 1 (5.9%) 2 (11.8%) 0.750
5–33% 6 (35.3%) 6 (35.3%) (P<0.0001)
>33–66% 7 (41.2%) 5 (29.4%)
>66% 3 (17.6%) 4 (23.5%)
Severity of lobular neutrophil infiltrate
Minimal 2 (11.8%) 3 (17.6%) 0.904
Moderate 8 (47.1%) 7 (41.2%) (P<0.0001)
Marked 7 (41.2%) 7 (41.2%)
Parenchymal involvement by
ballooning
No ballooning - -
<5% 1 (5.9%) 2 (11.8%) 0.183
>5–10% 1 (5.9%) 4 (23.5%) (P=0.160)
>10–20% 6 (35.3%) 3 (17.6%)
>20–50% 8 (47.1%) 7 (41.2%)
>50% 1 (5.9%) 1 (5.9%)
Canalicular cholestasis number of
bile plugs in canaliculi
None 5 (29.4%) 5 (29.4%) 0.174
<5 - 9 (52.9%) (P=0.033)
>5–10 1 (5.9%) 1 (5.9%)
>10–20 8 (47.1%) 2 (11.8%)
>20 3 (17.6%) -
Ductular cholestasis number of bile
plus in ductules
None 14 (82.4%) 14 (82.4%) 0.218
1 2 (11.8%) 3 (17.6%) (P=0.285)
2 - -
3 - -
>3 1 (5.9%) -
Mallory’s hyaline 14 (82.4%) 15 (88.2%) 0.767
(P=0.001)
Cholangiolitis 13 (76.5%) 12 (70.6%) –0.053
Polymorphs around and in ductule
lumen
(P=0.825)
Councilman bodies 9 (47.1%) 4 (23.5%) 0.029
(P=0.893)
There was an agreement between histopathologists regarding severity of parenchymal neutrophil infiltration in 16
out of 17 patients. Steatohepatitis was deemed marked in seven patients, moderate in seven and mild in two. The
24 h:30 min hepatic activity ratio was significantly higher in marked steatohepatitis (4.0 (3.0–4.6)) compared with
moderate (1.9 (1.6–3.0)) and mild (1.45 (1.2–1.7)) steatohepatitis (P=0.022; Figure 4). The 24 h:30 min ratio in pa-
tients with histologically mild steatohepatitis was similar to that in abstinent cirrhotics with hepatic decompensation
(P=0.25).
There was good interobserver agreement in parenchymal granulocyte quantification determined from
CD15-positive cell counts (r = 0.85, P<0.001). CD15-positivity count correlated modestly with the 24 h:30 min
ratio (Figure 4; r = 0.62; P=0.023).
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Figure 4. Comparison between 111In-leucocyte scintigraphy findings and liver histology in SAH
The 24 h:30 min hepatic activity ratios were significantly higher in marked compared with mild andmoderate steatohepatitis (pathol-
ogist #1 (A) and pathologist #2 (B)). CD15 quantification of parenchymal neutrophil infiltration correlated with 24 h:30 min activity
ratio (C).
Examples of 111In-leucocyte scintigraphy and corresponding liver biopsy sections in mild compared with marked
steatohepatitis are shown in Figure 5. No association was observed between the 24 h:30 min activity ratio and fibrosis
stage.
Clinical parameters, treatment response and survival
There was no correlation between the 24 h:30 min activity ratio and serum bilirubin (ρ = 0.02, P=0.9), peripheral
blood leucocyte counts (ρ = 0.28, P=0.25) or clinical measures of disease severity, including Child–Pugh score (ρ
= –0.17, P=0.5), DF (ρ = 0.16, P=0.5), GAHS (ρ = 0.29, P=0.23) or MELD (ρ = 0.26, P=0.29). Assessment of
treatment response in SAH was precluded in three patients who were treated as part of another placebo-controlled
trial. Of the remaining 16, 14 received CS and/or PTX, of whom 10 exhibited a clinical response following a week of
therapy. No significant difference was observed in the 24 h:30 min activity ratio between patients who responded to
therapy compared with non-responders (2.4 (1.6–3.8) compared with 2.3 (1.7–2.6)). Inpatient mortality (21%) was
not predicted by imaging findings. Furthermore, there was no association between histological findings and either
treatment response or in-hospital survival.
Microautoradiography
H&E-stained autoradiography undertaken in one patient with SAH demonstrated foci of cell-associated radioactivity
in areas of parenchymal neutrophil infiltrationwith low level background hepatic radioactivity (Figure 6). The 24 h:30
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Figure 5. Example 111In-leucocyte scintigraphy and corresponding liver histology in SAH patients with mild and marked
steatohepatitis
111In-leucocyte scintigraphy in patients with mild (A) and marked (B) steatohepatitis with corresponding Haematoxylin and Eosin
(H&E) stained liver biopsy sections (C,D respectively). Note increased diffuse lung activity at 30min post injection and hepatomegaly,
plus a hint of gut activity in the left mid-abdomen, in (B). The 24 h:30 min hepatic activity ratios were 1.2 and 3.5 respectively. Note
that in (B) lung activity clears by 24 hours.
min hepatic activity ratio in this patient was 4.5.
99mTc-nanocolloid scintigraphy
Hepatic-to-splenic uptake ratio of 99mTc-nanocolloidwas significantly lower in SAH (median 0.5 (0.4–1.4)) compared
with abstinent cirrhotics (2.3 (0.6–3.0)) and three historic controls without liver disease (4.2 (3.8–5.0); P=0.003;
Figure 7). In SAH patients, however, there was no correlation between 99mTc-nanocolloid liver/spleen ratios and
either the 24 h:30 min activity ratio (r = −0.04, P=0.9) or histological severity of steatohepatitis (r = −0.4, P=0.3).
Discussion
This proof-of-concept study shows for the first time that hepatic neutrophilmigration can be successfully imaged and
semiquantified using 111In-leucocyte scintigraphy. This provides not only a potentialmeans of diagnosis and outcome
prediction in SAH, but also, importantly, a platform for the assessment of new anti-inflammatory therapies for a range
of acute inflammatory liver disorders. An analogous scenario is inflammatory pulmonary disease in which there is
interest in using labelled neutrophils and eosinophils for assessing new therapies. While labelled ‘mixed’ leucocytes
are shown here to be appropriate for routine clinical use, labelled purified neutrophils would probably be preferable
for research applications.
Current European guidelines recognise the need for non-invasive diagnostic tools for SAH [3]. Abnormal leucocyte
scintigraphy in SAH was characterised by an increase in liver-associated radioactivity between 30 min and 24 h, not
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 6. Liver biopsy microautoradiography in SAH
Liver microautoradiographs in SAH from biopsy material obtained 24h post injection (PI) of 111In-labelled leucocytes. H&E stained
microautoradiographs at 40× (A) and 100× (B) objective magnification demonstrate foci of parenchymal granulocyte-associated
radioactivity, indicated by overlying clusters of black silver halide crystals, against a low level of background radioactivity. Corre-
sponding γ camera images 30 min (C) and 24 h (D) PI demonstrate a prominent increase in liver-associated radioactivity (24 h:30
min activity ratio of 4.5). Note that in (D) lung activity clears by 24h.
seen in abstinent cirrhotics or normal controls. The 24 h:30min hepatic activity ratio portrays intrahepatic neutrophil
migration as shown by correlation with measures of neutrophil infiltration on liver biopsy.
We hypothesised that, for whatever mechanistic reason but almost certainly including reduced hepatic blood flow,
physiological hepatic accumulation of 111In, both at 30 min as a result of impaired pooling, and 24 h as a result of
impaired destruction, would be sufficiently decreased in SAH to expose hepatic neutrophil migration as an increase
in liver-associated radioactivity between 30 min and 24 h. Consistent with impaired neutrophil destruction, hepatic
accumulation of 99mTc-nanocolloid was suppressed in SAH (Figure 7), corroborating the findings of earlier studies
indicating impaired Kupffer cell phagocytic function [12,24]. The increase in liver-associated 111In activity is almost
certainly, therefore, the result of neutrophil migration. This interpretation is supported by microautoradiography of
biopsy material obtained 24 h post-injection of 111In-leucocytes, which demonstrated, albeit in only one individ-
ual, discrete foci of cell-associated radioactivity in areas of neutrophil satellitosis within the lobular parenchyma.
Moreover, although it provides no insight into the mechanisms of cellular extravasation, CD15 expression correlated
significantly with the 24 h:30 min activity ratio.
Several extrahepatic features were noted on 111In-leucocyte scintigraphy. Prominent diffuse lung radioactivity at
30 min, clearing by 24 h, was a consistent finding in SAH, suggesting pulmonary vascular entrapment of primed
neutrophils without extravascular migration. These imaging features have been reported in several other disorders
associated with systemic neutrophil priming, including vasculitis [25] and severe inflammatory bowel disease [26].
Leucocyte kinetics associated with priming are different from those seen following labelling-induced leucocyte in-
jury, which gives immediate lung activity, markedly reduced 45 min recovery and decreased physiological uptake
10 c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 7. Technetium-99m (99mTc) nanocolloid scintigraphy
Example anterior γ camera images following 99mTc nanocolloid administration in severe AH (A), demonstrating liver ’drop out’
compared with inactive cirrhotic (B) and normal controls (C). Hepatic:splenic 99mTc-nanocolloid activity ratios (geometric mean of
counts/pixel) were significantly lower in SAH compared with both abstinent cirrhotics and normal controls, consistent with severely
impaired liver reticuloendothelial function (D).
in the spleen and bone marrow. Our scintigraphic findings of priming add to the existing ex vivo evidence for sys-
temic neutrophil priming in SAH [27] and suggest that priming also occurs, albeit to a lesser degree, in patients with
compensated chronic liver disease.
Labelled leucocyte recovery is probably the best benchmark of cell ‘health’ following labelling. Themarginatedneu-
trophil pool (which in health resides in the liver, spleen and bone marrow) [16] is in equilibrium with the circulating
pool, and represents∼50% of the total blood neutrophil pool. Maximum recovery is therefore∼50% of administered
activity. The increased recovery in SAH, despite increased pulmonary margination, suggests a pathophysiological
shift in granulocyte margination away from the liver, in keeping with clearly reduced hepatic activity at 30 min post
injection in SAH (Figure 2). On the other hand, delayed pulmonary transit would be expected to reduce recovery.
Abnormal gut radioactivity was observed in a fifth of patients with SAH, in the absence of gastrointestinal (GI)
symptoms or apparent disease. Because ‘free’ 111In does not enter the gut, distal transit of 111In on delayed imaging
suggests luminal transit of labelled cells within faeces. The cause remains unclear andwarrants further study, although
potential explanations include disposal of intrahepatic neutrophils cells via bile, or more likely a sequel of portal
hypertension.
We did not identify patients with clinically suspected SAH where histology refuted or altered the diagnosis, as
others have shown [4,6]. Our data, however, demonstrated significant heterogeneity in the severity of steatohepatitis
that was independent of clinical and laboratory disease markers, but predicted by 111In-leucocyte scintigraphy. No
correlation was observed between clinical prognostic scores commonly used to judge disease severity and either the
24:30 min activity ratio or histological severity of steatohepatitis. However, most patients had clinically advanced
disease making it difficult to further stratify according to disease severity.
Although recent clinical trials have questioned the benefit from CS [20], they remain widely used in medical man-
agement of SAH. Previous authors described a positive association between parenchymal neutrophil infiltration and
clinical CS response in SAH [9]. Predicting response to therapy would be useful, particularly given the high rates of
infection and poor survival in CS non-responders [28]. We did not demonstrate a relationship between scintigraphic
findings and either treatment response or in-hospital mortality. Furthermore, we saw no association between steato-
hepatitis severity and either treatment response or survival, probably because of heterogeneity in prescribed therapies
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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and small patient numbers. A larger study, powered to assess these specific end points, would be required to assess
the prognostic value of 111In-leucocyte scintigraphy.
Further study limitations are as follows. For the convenience that would be important in routine clinical studies,
we used labelled ‘mixed’ leucocytes. However, although mixed leucocytes clearly demonstrate the feasibility of imag-
ing hepatic inflammation, 111In-labelled purified neutrophils would be preferable for research applications. 111In is
preferable to 99mTc because of its greater cell labelling stability.Moreover, 111In preferentially labels neutrophils, unlike
99mTc-hexamethylpropylamine oxime (HMPAO), which is strongly selective for eosinophils [29].
Differentiation of SAH from other acute deteriorations of chronic liver disease, particularly end-stage cirrhosis or
decompensation due to infection, is often challenging and any non-invasive diagnostic test for SAH would need to
distinguish it from decompensation. Although they will form the cohort for future studies, we did not include a con-
trol group with decompensated cirrhosis at this stage of our work as our primary aim was to establish the feasibility
of imaging hepatic inflammation with radiolabelled leucocytes in homogeneous patient cohorts. A decompensated
group would be highly heterogeneous and likely to include patients with ongoing or recent alcohol use, in whom sub-
clinical AH would be a significant unmeasured confounder. Confident inclusion of such patients, moreover, would
have required TJB for the sole purpose of excluding those with histologically active steatohepatitis, and would there-
fore have raised significant ethical issues. TJB in SAH, in contrast, is clinically justifiable and indeed standard of care
in some centres. Liver biopsy is not common practice in other forms of ARLD, which are invariably associated with
ongoing alcohol use. Given their high prevalence of asymptomatic subclinical steatohepatitis, active heavy drinkers
[30], other than SAH patients, were not included. Patients with cirrhosis were therefore recruited following at least 6
months abstinence, to allow sufficient time for resolution of underlying steatohepatitis.
In conclusion, we have demonstrated how 111In-labelled leucocyte scintigraphy can be exploited to detect hepatic
neutrophil migration in SAH. The technique has potential clinical application as a non-invasive means of diagnosing
this condition and assessing the severity of liver inflammation without the need for liver biopsy. Importantly, it also
has the potential to provide a platform for experimental therapies aiming to inhibit intrahepatic neutrophilmigration.
Evaluation of leucocyte kinetics in other forms of acute and acute-on-chronic liver disease would be of interest.
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